24 November 2014
A new study has found that patients who receive more cells during treatment have better benefits after the therapy.
The research saw 161 heart attack patients given their own bone marrow cells, which were selected for their ability to promote self-healing. These were reinjected into the heart in a bid to improve recovery of the organ.
All participants received the standard stent placement and were only enrolled onto the study if their ejection fraction was less than 48 per cent - an indication that their heart was not pumping effectively.
Some were given a placebo, while those receiving the therapy saw the number of cells vary significantly.
The team, led by Dr Arshed Quyyumi, professor of medicine at Emory University School of Medicine, used several factors to measure success such as MACE (major adverse cardiac events) and ejection fraction.
Some 14 per cent of control patients suffered MACE, compared to 17 per cent of those of who received less than 14 million cells and ten per cent of those who received more than 14 million cells. It occurred in just seven per cent of those who received greater than 20 million cells. Mortality was 3.6 per cent in the control group, and zero in the entire treatment group.
Posted by Philip Briggs
Health News is provided by Adfero in collaboration with Spire Healthcare. Please note that all copy above is ©Adfero Ltd. and does not reflect views or opinions of Spire Healthcare unless explicitly stated. Additional comments on the page from individual Spire consultants do not necessarily reflect the views or opinions of other consultants or Spire Healthcare.